title: Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer.
abstract: BACKGROUND
  In metastatic breast cancer patients who have had prior exposure to anthracyclines, single agents induce less than 15% and combination chemotherapy less than 20%-30% of objective responses. Therefore more active and tolerable salvage regimens are needed.
  
  
  METHODS
  Forty-three patients with advanced breast cancer pretreated with 1-5 (median 2) different chemotherapy regimens were entered into this phase I/II trial. Treatment consisted of folinic acid (FA) (500 mg/m2, i.v., 2-hour infusion) followed by a 24-hour infusion of 5-fluorouracil (FU) which was escalated from 1.5 g/m2 (dose level (dl 1)), to 1.8 g/m2 (dl 2) to 2.1 g/m2 (dl 3). Therapy was given as outpatient treatment once weekly times 6 followed by a 2-week rest.
  
  
  RESULTS
  HD-FU/FA was well tolerated. No dose-limiting toxicity occurred at dl 1 or 2. Only 3/32 (9%) patients had WHO grade 3/4 toxicities (gastrointestinal toxicities, hand-foot-syndrome) at dl 3. The response rate for all 32 of the patients treated at dl 3 was 41% (13/32). In the 24 patients with anthracycline-refractory disease, a response rate of 41% (10/24) was achieved. The median remission duration was 11 months and the median survival time 19 months.
  
  
  CONCLUSIONS
  This schedule of FU/FA is a safe outpatient treatment with substantial activity in intensively pretreated breast cancer patients.
authors.affiliation: Department of Internal Medicine, Essen University Medical School, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Wilke
authors.forename: U
authors.initials: U
authors.lastname: Klaassen
authors.forename: W
authors.initials: W
authors.lastname: Achterrath
authors.forename: M
authors.initials: M
authors.lastname: Losch
authors.forename: U
authors.initials: U
authors.lastname: Vanhoefer
authors.forename: J
authors.initials: J
authors.lastname: Hayungs
authors.forename: A
authors.initials: A
authors.lastname: Harstrick
authors.forename: M
authors.initials: M
authors.lastname: Stahl
authors.forename: W
authors.initials: W
authors.lastname: Eberhardt
authors.forename: R
authors.initials: R
authors.lastname: Becher
authors.forename: S
authors.initials: S
authors.lastname: Seeber
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010865:Pilot Projects
chemical_list: D002955:Leucovorin; D005472:Fluorouracil